Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rolapitant Palonosetron for Nausea and Vomiting in Lung Cancer Chemoradiotherapy
NCT07442890Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- Small Molecules
01
Overview
Randomised trial of rolapitant + palonosetron in Nausea and Vomiting (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Complete Remission Rate at 6 weeks. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
rolapitant + palonosetron
03
Conditions
Nausea and Vomiting
Beyond the preview
Go deeper on NCT07442890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07442890.